StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3034% above fair value
$36.48+0.02 (+0.05%)

Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Pacira BioSciences's revenue for the twelve months ending Jun 30, 2026 was $746.16M, up 5.7% year over year. For fiscal 2025 it was $726.41M, up 3.6% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $726.41M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$726.41M+3.6%
FY2024Dec 31, 2024$700.97M+3.9%
FY2023Dec 31, 2023$674.98M+1.2%
FY2022Dec 31, 2022$666.82M+23.1%
FY2021Dec 31, 2021$541.53M+26.0%
FY2020Dec 31, 2020$429.65M+2.0%
FY2019Dec 31, 2019$421.03M+24.8%
FY2018Dec 31, 2018$337.28M+17.7%
FY2017Dec 31, 2017$286.63M+3.7%
FY2016Dec 31, 2016$276.37M+11.0%
FY2015Dec 31, 2015$249.00M+26.0%
FY2014Dec 31, 2014$197.67M+131.1%
FY2013Dec 31, 2013$85.55M+118.9%
FY2012Dec 31, 2012$39.08M+149.1%
FY2011Dec 31, 2011$15.69M+7.7%
FY2010Dec 31, 2010$14.56M-3.0%
FY2009Dec 31, 2009$15.01M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$192.40M+6.2%
Q1 FY2026Mar 31, 2026$177.38M+5.0%
Q4 FY2025Dec 31, 2025$196.87M+5.1%
Q3 FY2025Sep 30, 2025$179.52M+6.5%
Q2 FY2025Jun 30, 2025$181.10M+1.7%
Q1 FY2025Mar 31, 2025$168.92M+1.1%
Q4 FY2024Dec 31, 2024$187.25M+3.3%
Q3 FY2024Sep 30, 2024$168.57M+2.8%
Q2 FY2024Jun 30, 2024$178.02M+5.0%
Q1 FY2024Mar 31, 2024$167.12M+4.2%
Q4 FY2023Dec 31, 2023$181.24M+5.4%
Q3 FY2023Sep 30, 2023$163.93M-2.1%
Q2 FY2023Jun 30, 2023$169.47M+0.0%
Q1 FY2023Mar 31, 2023$160.34M+1.5%
Q4 FY2022Dec 31, 2022$171.96M+8.0%
Q3 FY2022Sep 30, 2022$167.47M+31.1%
Q2 FY2022Jun 30, 2022$169.41M+24.9%
Q1 FY2022Mar 31, 2022$157.99M+32.7%
Q4 FY2021Dec 31, 2021$159.19M+21.5%
Q3 FY2021Sep 30, 2021$127.72M+8.7%
Q2 FY2021Jun 30, 2021$135.59M+79.6%
Q1 FY2021Mar 31, 2021$119.03M+12.6%
Q4 FY2020Dec 31, 2020$130.97M+7.0%
Q3 FY2020Sep 30, 2020$117.48M+12.2%
Q2 FY2020Jun 30, 2020$75.51M-26.4%
Q1 FY2020Mar 31, 2020$105.68M+15.7%
Q4 FY2019Dec 31, 2019$122.42M+28.7%
Q3 FY2019Sep 30, 2019$104.69M+25.4%
Q2 FY2019Jun 30, 2019$102.60M+22.0%
Q1 FY2019Mar 31, 2019$91.31M+22.4%
Q4 FY2018Dec 31, 2018$95.12M+20.3%
Q3 FY2018Sep 30, 2018$83.45M+23.9%
Q2 FY2018Jun 30, 2018$84.11M+18.6%
Q1 FY2018Mar 31, 2018$74.61M+7.7%
Q4 FY2017Dec 31, 2017$79.08M+8.5%
Q3 FY2017Sep 30, 2017$67.34M-1.5%
Q2 FY2017Jun 30, 2017$70.93M–
Q1 FY2017Mar 31, 2017$69.28M–
Q4 FY2016Dec 31, 2016$72.90M–
Q3 FY2016Sep 30, 2016$68.36M–

More Pacira BioSciences figures

See a number that looks wrong?